("Faron" or the "Company")
Faron confirms plans for the coming months under new leadership
- Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next month
- Incoming CEO,
Press Release,
Initial data from the ongoing Phase 2 part of the BEXMAB trial, evaluating the safety and efficacy of bexmarilimab in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS), is expected to be announced during the week commencing
Given the promising data already seen in the Phase 1 part of the trial, among HMA-failed MDS patients who have no approved treatment options, the Company plans to approach the
"2024 is set to be a pivotal year for Faron in the delivery of key milestones that will be critical to the further development of bexmarilimab," said Dr.
For more information please contact:
Investor Contact
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
ICR Consilium
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Phone: +44 (0) 207 213 0880
Phone: +44 (0) 20 7418 8900
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.
https://news.cision.com/faron-pharmaceuticals-oy/r/faron-confirms-plans-under-new-leadership,c3961857
https://mb.cision.com/Main/19398/3961857/2733140.pdf
(c) 2024 Cision. All rights reserved., source